ATTD International Consensus on the use of SGLT1&2 inhibitors in treating T1D – ORLANDO 2018
Recent study results show a significant clinical benefit of adjunct therapy with SGLT1&2 inhibitors in addition to insulin in type 1 diabetes. However, this is accompanied by slightly higher DKA rates than placebo in several studies.
In June 2018, the ATTD convened a consensus meeting with an international panel of 30 physicians and researchers with expertise in using SGLT-inhibitor therapy in order to find ways to mitigate DKA and euDKA risk. These are now summarized in a publication in Diabetes Care.
Diabetes Care 2019; 42:1147-1154